CompletedPhase 2NCT01212744

Safety, Tolerability, and Efficacy Study of rAvPAL-PEG Administered Daily in Subjects With Phenylketonuria (PKU)

Studying Classic phenylketonuria

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
BioMarin Pharmaceutical
Principal Investigator
Ari Gershman, MD, M.D
BioMarin Pharmaceutical
Intervention
rAvPAL-PEG(drug)
Enrollment
16 enrolled
Eligibility
16-70 years · All sexes
Timeline
20112015

Study locations (9)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01212744 on ClinicalTrials.gov

Other trials for Classic phenylketonuria

Additional recruiting or active studies for the same condition.

See all trials for Classic phenylketonuria

← Back to all trials